BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9849428)

  • 21. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
    Rogers PM; Beale PJ; Al-Moundhri M; Boxall F; Patterson L; Valenti M; Raynaud F; Hobbs S; Johnston S; Kelland LR
    Int J Cancer; 2002 Feb; 97(6):858-63. PubMed ID: 11857368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
    Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
    Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
    Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
    Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1).
    Sugimoto M; Martin N; Wilks DP; Tamai K; Huot TJ; Pantoja C; Okumura K; Serrano M; Hara E
    Oncogene; 2002 Nov; 21(53):8067-74. PubMed ID: 12444543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas.
    Saegusa M; Machida B D; Okayasu I
    Cancer; 2001 Sep; 92(5):1177-89. PubMed ID: 11571731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53.
    Lee CC; Ichihara T; Yamamoto S; Wanibuchi H; Sugimura K; Wada S; Kishimoto T; Fukushima S
    Carcinogenesis; 1999 Sep; 20(9):1697-708. PubMed ID: 10469613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
    Schmidt M; Fan Z
    Oncogene; 2001 Sep; 20(43):6164-71. PubMed ID: 11593424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity.
    Wrighton KH; Prêle CM; Sunters A; Yeudall WA
    Int J Cancer; 2004 Dec; 112(5):760-70. PubMed ID: 15386387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia.
    Said TK; Moraes RC; Singh U; Kittrell FS; Medina D
    Cell Growth Differ; 2001 Jun; 12(6):285-95. PubMed ID: 11432803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of sdi1, a potent inhibitor of cdk2 kinase, cdk2 and G1 cyclins and mutation of sdi1 in human gastric carcinomas].
    Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Tahara H; Noda A; Tahara E
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():180. PubMed ID: 7611786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
    Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer.
    Wan M; Cofer KF; Dubeau L
    Br J Cancer; 1996 Jun; 73(11):1398-400. PubMed ID: 8645586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression.
    Zhang D; Vuocolo S; Masciullo V; Sava T; Giordano A; Soprano DR; Soprano KJ
    Oncogene; 2001 Nov; 20(55):7935-44. PubMed ID: 11753676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
    Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
    J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells.
    Gupta S; Hussain T; Mukhtar H
    Arch Biochem Biophys; 2003 Feb; 410(1):177-85. PubMed ID: 12559991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.